A COMPARATIVE BINDING OF PLATINUM ANTITUMOR COMPOUNDS TO PLASMA-PROTEINS IN THE RAT (INVIVO) AND MOUSE (INVITRO)

被引:20
作者
PERERA, A
JACKSON, H
SHARMA, HL
MCAULIFFE, CA
FOX, BW
机构
[1] UNIV MANCHESTER,SCH MED,MANCHESTER M13 9PT,LANCS,ENGLAND
[2] UNIV MANCHESTER,INST SCI & TECHNOL,DEPT CHEM,MANCHESTER M60 1QD,LANCS,ENGLAND
[3] CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND
关键词
PLATINUM-195M; PLASMA BINDING; CISPLATIN; CARBOPLATIN; IPROPLATIN;
D O I
10.1016/0009-2797(92)90062-P
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasma protein binding of Pt-195m-labelled cisplatin, carboplatin and iproplatin has been studied in vivo in rat and in vitro in mouse, using both electrophoresis and trichloroacetic acid precipitation. After intravenous injection plasma clearance rates were biphasic for all 3 compounds, (t1/2 alpha 13 - 17 min) but cisplatin was retained thereafter longer than the others. By 5 min, gel electrophoresis showed protein labelling with all 3 drugs but none involved low mol. wt. proteins (< 16 kDa). At 2 h a notable proportion of the protein bound platinum was associated with the latter components. There was a general resemblance between the distribution patterns of cisplatin and carboplatin whereas iproplatin showed a persistent retention of the label with time to higher mol. wt. proteins. From in vitro incubation with mouse plasma, rates of interaction respectively were cisplatin t1/2 alpha, 35 min, beta 8 h, carboplatin t1/2, 44 h and iproplatin t1/2, 104 h. By electrophoresis the protein bound fraction pattern (1 h) was again similar for cisplatin and carboplatin with virtually no binding to low mol. wt. proteins. After 24 h these were now involved to a high degree (40%). Iproplatin showed relatively marked binding to proteins of higher mol. wt. but no transfer with time to the low mol. wt. protein zone. A possible explanation is the need for in vivo metabolism for this compound as manifest in the rat. It is suggested that the significance of interaction with low mol. wt. proteins merits further investigation in relation to the antitumour and toxicological actions of these drugs.
引用
收藏
页码:199 / 213
页数:15
相关论文
共 33 条
[21]   DISTRIBUTION OF CIS-PLATIN IN BLOOD [J].
MANAKA, RC ;
WOLF, W .
CHEMICO-BIOLOGICAL INTERACTIONS, 1978, 22 (2-3) :353-358
[22]   INVITRO PLASMA-BINDING OF SOME 2ND GENERATION ANTITUMOR PLATINUM COMPLEXES [J].
MOMBURG, R ;
BOURDEAUX, M ;
SARRAZIN, M ;
ROUX, F ;
BRIAND, C .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1985, 10 (01) :77-83
[23]  
PENDYALA L, 1982, CANCER TREAT REP, V66, P509
[24]  
PENDYALA L, 1983, CANCER CHEMOTH PHARM, V11, P23
[25]  
Putnam FW, 1975, PLASMA PROTEINS, V1, P141
[26]  
Repta A.J., 1980, CISPLATIN, P285, DOI [10.1016/b978-0-12-565050-2.50022-x, DOI 10.1016/B978-0-12-565050-2.50022-X]
[27]  
Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0
[28]   PLATINUM COMPOUNDS - A NEW CLASS OF POTENT ANTITUMOUR AGENTS [J].
ROSENBERG, B ;
VANCAMP, L ;
TROSKO, JE ;
MANSOUR, VH .
NATURE, 1969, 222 (5191) :385-+
[29]  
SIDDIK ZH, 1984, PLATINUM COORDINATIO, P90
[30]  
Stjernholm R. L., 1986, United States Patent No, Patent No. 4590001